NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Travere Therapeutics, Inc. TVTX
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$490.7M
▲ 110.5% vs FY2024
EPS · FY25
$-0.29
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-29.4%
Net margin · FY25
-5.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 490.7M
Revenue, FY2025 · full 16-year series below
Revenue
Net income
The company lost 5 cents on every revenue dollar this year.
Per share
USD -0.29
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-29.4%
Return on equity, FY2025
ROE
Operating margin-12.8%
Net margin-5.2%
Return on assets-4.3%
Each USD of equity lost 29 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+19.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+64.9%
+19.9%
+17.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.09B
Shares outstanding, FY2025
Change, 5 years+74.0%
Change, 10 years+149.3%
The share count grew 74% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 605.2M
total assets, end of FY2025
Total assetsUSD 605.2M
EquityUSD 114.8M
CashUSD 93.0M
Current ratio2.74×
Equity funds 19% of total assets.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.5
0.2
0.1
0.1
0.1
0.2
0.2
0.2
0.2
0.1
0.1
0.0
0.0
·
0.0
0.0
Operating income $B
−0.1
−0.3
−0.4
−0.3
−0.2
−0.2
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
·
·
EBITDA $B
−0.0
−0.3
−0.3
−0.3
−0.2
−0.2
−0.1
−0.1
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
0.0
−0.0
−0.0
−0.0
0.0
·
·
·
Net income $B
−0.0
−0.3
−0.1
−0.3
−0.2
−0.2
−0.1
−0.1
−0.1
−0.0
0.1
−0.1
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.29
−4.08
−1.50
−4.37
−3.01
−3.56
−3.46
−2.54
−1.54
−1.29
3.17
−4.43
−2.44
−8.29
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−29.4
−247.4
−91.4
−161.5
−70.2
−78.4
−54.3
−33.6
−19.9
−15.8
89.2
·
·
·
·
·
Shares out B
0.09
0.09
0.08
0.06
0.06
0.05
0.04
0.04
0.04
0.04
0.04
0.03
0.02
0.01
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
42 of 42
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed